Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Condensed Consolidated Statements of Operations [Abstract]
Product and service revenue	$ 4,165,008	$ 4,273,385	$ 17,339,463	$ 18,711,555
Research and development contract revenue	461,808	502,269	1,229,734	1,475,338
Total revenue	4,626,816	4,775,654	18,569,197	20,186,893
Cost of product and service revenue	7,812,018	10,848,860	24,783,518	28,552,076
Cost of research and development contract revenue	730,486	791,322	1,883,361	2,389,844
Research and development expense	768,965	1,284,975	2,343,030	4,089,509
Selling, general and administrative expenses	2,753,030	3,053,434	8,849,730	10,556,495
Amortization of intangible assets	562,896	578,090	1,704,917	1,726,854
Operating loss	(8,000,579)	(11,781,027)	(20,995,359)	(27,127,885)
Interest and other income	26,028	80,046	83,109	171,260
Change in fair value of common stock warrant liability	(8,206,429)	1,434,866	(16,171,061)	3,726,667
Interest and other expense	(124,651)	(59,349)	(354,180)	(158,162)
Gain on sale of equity interest in joint venture			3,234,717
Loss before income taxes	(16,305,631)	(10,325,464)	(34,202,774)	(23,388,120)
Income tax benefit	410,259		410,259
Net loss attributable to the Company	(15,895,372)	(10,325,464)	(33,792,515)	(23,388,120)
Preferred stock dividends declared	(51,908)		(69,211)
Net loss attributable to common shareholders	$ (15,947,280)	$ (10,325,464)	$ (33,861,726)	$ (23,388,120)
Loss per share:
Basic and diluted	$ (0.19)	$ (0.27)	$ (0.51)	$ (0.71)
Weighted average number of common shares outstanding	84,150,851	37,977,052	67,194,806	33,107,175